TY - JOUR
TI - Pomalidomide plus low‐dose dexamethasone in relapsed/refractory multiple myeloma patients: Results of the real‐world “powerful” study
AU - Terpos, E.
AU - Repousis, P.
AU - Lalayanni, C.
AU - Hatjiharissi, E.
AU - Assimakopoulou, T.
AU - Vassilopoulos, G.
AU - Pouli, A.
AU - Spanoudakis, E.
AU - Michalis, E.
AU - Pangalis, G.
AU - Ntanasis‐stathopoulos, I.
AU - Poziopoulos, C.
AU - Kyrtsonis, M.-C.
AU - Pappa, V.
AU - Symeonidis, A.
AU - Georgopoulos, C.
AU - Zikos, P.M.
AU - Gavriatopoulou, M.
AU - Papadaki, H.A.
AU - Dadakaridou, M.
AU - Karvounis‐marolachakis, K.
AU - Katodritou, E.
JO - Journal of Clinical Medicine Research
PY - 2021
VL - 10
TODO - 7
SP - null
PB - MDPI
SN - 1918-3003, 1918-3011
TODO - 10.3390/jcm10071509
TODO - allopurinol;  antianemic agent;  antibiotic agent;  anticoagulant agent;  antifungal agent;  antivirus agent;  bendamustine;  bortezomib;  carfilzomib;  cisplatin;  creatinine;  cyclophosphamide;  daratumumab;  dexamethasone;  doxorubicin;  etoposide;  febuxostat;  filgrastim;  immunoglobulin A;  immunoglobulin G;  ixazomib;  lactate dehydrogenase;  lenalidomide;  melphalan;  panobinostat;  pomalidomide;  selinexor;  steroid;  sulfamethoxazole;  thalidomide;  trimethoprim;  vinblastine;  vincristine, acute kidney failure;  adverse drug reaction;  aged;  anemia;  Article;  autologous stem cell transplantation;  backache;  cancer combination chemotherapy;  cancer patient;  cancer recurrence;  clinical evaluation;  cohort analysis;  controlled study;  deep vein thrombosis;  diarrhea;  disease exacerbation;  diseases;  drug dose reduction;  drug efficacy;  drug safety;  drug utilization;  drug withdrawal;  fatality;  female;  follow up;  human;  incidence;  infection;  lactate dehydrogenase blood level;  low drug dose;  major clinical study;  male;  medical record review;  minimal residual disease;  multiple cycle treatment;  multiple myeloma;  neutropenia;  neutrophil count;  observational study;  overall response rate;  platelet count;  progression free survival;  prospective study;  recommended drug dose;  relapse;  retrospective study;  stomach hemorrhage;  thrombocytopenia;  thrombosis prevention;  treatment duration;  treatment indication;  treatment response;  treatment response time;  urinary tract infection
TODO - The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low‐dose dexamethasone (POM/LoDex) therapy in relapsed/re-fractory multiple myeloma in routine care in Greece. Ninety‐nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 Feb-ruary 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third‐line treatment. During the treatment period (median: 8.3 months; range: 0.3–47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow‐up period of 13.8 months (Kaplan–Meier estimate), the median progression‐free survival (PFS) was 10.5 months (95% CI: 7.4–14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow‐up (N = 75), POM‐related adverse event incidence rate was 42.7% (serious: 18.7%; grade ≥ 3 hematological POM‐related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real‐world study, POM/LoDex displayed a long PFS with no new safety signals emerging. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ER -